Vebreltinib for advanced clear cell sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests the drug vebreltinib for people with advanced or spreading clear cell sarcoma. The goal is to see if it can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 12 years old
- Have a type of cancer called clear cell sarcoma that cannot be removed by surgery or has spread
- Be in generally good health, with normal heart, liver, kidney, and blood function
- Agree to use reliable birth control during treatment and for 12 months after
- Cannot have had specific prior treatments like cabozantinib or other MET inhibitors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug called tebentafusp can help people with advanced clear cell sarcoma that cannot be removed by surgery or has spread. It is for people with a specific immune marker (HLA-A*02:01) whose disease has gotten worse.
This trial tests a new drug called vebreltinib combined with standard chemotherapy for advanced non-small cell lung cancer (a common type of lung cancer) in patients whose tumors show high levels of a protein called MET. The goal is to see if this combination can slow cancer growth better than chemotherapy alone.
This trial tests a combination of chemotherapy, radiation, and two newer drugs (anlotinib and bempegaldesleukin) for people with advanced soft tissue sarcoma that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and bevacizumab) for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if this combination can help when other treatments have stopped working.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This trial tests a drug called vebreltinib before surgery for people with a specific type of lung cancer (MET exon 14 skipping mutation) that is at a stage where it can be removed. The goal is to see if the drug can shrink the tumor before surgery, making the operation more successful.
Hear when a new Clear Cell Sarcoma (CCS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.